Funding for this research was provided by:
European Molecular Biology Organization
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA197623)
Received: 14 December 2021
Accepted: 27 June 2022
First Online: 8 August 2022
: K.P. serves on the Scientific Advisory Board of Acrivon Therapeutics, Vividion Therapeutics, Scorpion Therapeutics and the Novartis Institute for BioMedical Research, holds equity options in Scorpion Therapeutics, is a consultant to Aria Pharmaceuticals, received honorarium from AstraZeneca and New Equilibrium Biosciences, and has an institutional research agreement with Novartis. The remaining authors declare no competing interests.